Keyphrases
Unresectable Hepatocellular Carcinoma
100%
Overall Survival
100%
Molecular Targeted Agents
100%
Second-line Treatment
100%
Post-progression Survival
100%
Progression-free Survival
55%
Strong Correlation
33%
Regorafenib
22%
Sequential Therapy
22%
Hepatocellular Carcinoma
22%
Ramucirumab
22%
Cabozantinib
22%
Systemic Treatment
11%
Hepatic Functional Reserve
11%
Survival Benefit
11%
Disease Progression
11%
PubMed Database
11%
Weak Correlation
11%
Systematic Literature Review
11%
Pharmacology, Toxicology and Pharmaceutical Science
Overall Survival
100%
Liver Cell Carcinoma
100%
Molecular Target
100%
Progression Free Survival
55%
Regorafenib
22%
Ramucirumab
22%
Cabozantinib
22%
Systemic Treatment
11%
Disease Exacerbation
11%
Nursing and Health Professions
Liver Cell Carcinoma
100%
Overall Survival
100%
Progression Free Survival
55%
Ramucirumab
22%
Regorafenib
22%
Cabozantinib
22%
Systematic Review
11%
Medline
11%
Systemic Therapy
11%
Disease Exacerbation
11%
Medicine and Dentistry
Hepatocellular Carcinoma
100%
Overall Survival
100%
Progression Free Survival
55%
Regorafenib
22%
Ramucirumab
22%
Cabozantinib
22%
Systemic Therapy
11%
Systematic Review
11%
Disease Exacerbation
11%
Immunology and Microbiology
Overall Survival
100%
Progression Free Survival
55%
Ramucirumab
22%
Cabozantinib
22%
Regorafenib
22%
Medline
11%
Agricultural and Biological Sciences
Ramucirumab
100%
Systematic Review
50%